Current Report Filing (8-k)
April 09 2019 - 5:02PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
April 5, 2019
Alliqua
BioMedical, Inc.
(Exact Name of Registrant as Specified in its Charter)
Delaware
|
|
001-36278
|
|
58-2349413
|
(State or other jurisdiction
of incorporation)
|
|
(Commission File Number)
|
|
(IRS Employer
Identification No.)
|
|
|
|
2150 Cabot Blvd., West
Suite B
Langhorne, PA
|
|
19047
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrant’s telephone number, including
area code: (215) 702-8550
Former name or former address, if changed since last report)
|
Check the appropriate box below if the Form
8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
¨
|
Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement communications
pursuant to Rule 13e-4 (c) under the Exchange Act (17 CFR 240.13e-4(c)
|
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
¨
If an emerging growth company, indicate
by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act.
¨
|
Item 5.02
|
Departure of Directors
or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
|
Effective as of
April 5, 2019, the
Board of Directors
of Alliqua BioMedical, Inc. (the “Company”)
appointed Mr. David Johnson, the Company’s Chief Executive Officer, to serve as its principal financial officer, effective
immediately. Mr. Johnson was appointed as a result of the Company’s prior Chief Financial Officer, Mr. Joseph Warusz, resigning
from his position effective as of March 18, 2019.
No new compensatory
or severance arrangements were entered into in connection with Mr. Johnson’s appointment as principal financial officer.
Mr. Johnson, 60, has served on the board
of directors of the Company since November 2012 and has served as the President and Chief Executive Officer of the Company since
February 2013. Mr. Johnson was formerly President of the ConvaTec Division of Bristol-Myers Squibb, Inc. until 2008 when he orchestrated
a sale of the division from its pharmaceutical parent to Avista Capital Partners and Nordic Capital in a deal valued at $4.1 billion.
Concurrently, he acquired and integrated the assets of Copenhagen-based Unomedical to expand ConvaTec Inc.’s manufacturing
and infrastructure into Europe. From 2008 through 2012, Mr. Johnson served as the Chief Executive Officer of ConvaTec Inc. Prior
to his tenure with ConvaTec Inc., Mr. Johnson held several senior positions in the U.S., Europe and Canada with Zimmer Inc., Fisher
Scientific, and Baxter Corporation. He served as a member of ConvaTec Inc.’s board of directors and the board of the Advanced
Medical Technology Association (AdvaMed), where he chaired the Global Wound Sector Team for four years. Mr. Johnson received an
Undergraduate Business Degree in Marketing from the Northern Alberta Institute of Technology in Edmonton, Alberta, Canada, completed
the INSEAD Advanced Management Program in Fontainbleau, France, and is a fellow from the Wharton School of the University of Pennsylvania.
Mr. Johnson has no family relationships
with any director or executive officer of the Company and has not been involved in any related person transaction that would require
disclosure pursuant to Item 404(a) of Regulation S-K.
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
ALLIQUA BIOMEDICAL, INC.
|
|
|
|
|
|
|
Dated: April 9, 2019
|
By:
|
/s/ David I. Johnson
|
|
|
Name: David I. Johnson
|
|
|
Title: Chief Executive Officer
|
Alliqua, Inc. (NASDAQ:ALQA)
Historical Stock Chart
From Apr 2024 to May 2024
Alliqua, Inc. (NASDAQ:ALQA)
Historical Stock Chart
From May 2023 to May 2024